Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Placement

<< Previous

Bullboard Posts

Next >>

Comment by palinc2000on Jan 14, 2021 12:51pm

167 Views

Post# 32297599

RE:RE:RE:RE:RE:RE:RE:RE:Placement

This means that a very small increase in the SP will allow the Unit Holders to sell the shares in the open market at or above the unit cost and simply hold the warrants at no cost and participate in any upside above the warrant exercise price
Is there a hold period before the shares are separated from the Unit?

<< Previous

Bullboard Posts

Next >>

Canadian artificial intelligence ETFs